GSK Sells Near-Commercial Liver Drug Linerixibat to Alfasigma for $690 Million Amid Industry-Wide Portfolio Rationalization

　　【Pharmaceutical Network Industry DynamicsRecently, GSK announced the sale of the global rights to linerixibat, a liver disease drug not yet on the market, to Alfasigma for $690 million. As an ileal bile acid transporter (IBAT) inhibitor currently under development, linerixibat’s core target is treating cholestatic pruritus in patients with PBC.
 

Clinical data show that, compared with placebo, linerixibat can rapidly, significantly, and continuously improve cholestatic pruritus symptoms in PBC patients. It also effectively alleviates sleep disturbances related to pruritus, helping patients restore normal sleep. Moreover, it demonstrates good safety and tolerability.
 

Industry analysts believe that the sale of linerixibat at the critical juncture just before FDA approval and its impending commercialization phase is actually a rational decision by GSK to optimize its pipeline, focus on core businesses, and control risks. It is reported that the field of liver disease where linerixibat is positioned is not one of GSK's core areas of strength, and its R&D and commercialization resources in this area are relatively limited. Significant funding and manpower would be required to advance the subsequent development and commercialization of the drug, while also facing numerous market uncertainties in the future. By selling linerixibat, GSK can quickly obtain a substantial cash flow and avoid the subsequent risks associated with R&D and commercialization.
 

Notably, in recent years, GSK has actually been focusing on its core areas of expertise such as respiratory, infectious diseases, oncology, and immunology. The company has continuously divested non-core pipeline assets to optimize resource allocation and enhance R&D efficiency as well as financial returns. For instance, as early as 2016, GSK sold its equity stake in Nanjing Meirui Pharmaceutical, the Meirui factory, and the local production and supply business related to three urology products held by the group's China division. The buyer was CareDx Pharmaceutical Holdings Group.
 

In December 2020, GSK announced that it had sold its Mississauga plant in Ontario, Canada, to Bora Pharmaceuticals. In May 2024, GSK stated that it would sell all of its remaining shares in the consumer health company Haleon...
 

In addition to GSK, many pharmaceutical companies in recent years have also been driving a wave of transactions within the industry focused on "core businesses, rapid monetization, and optimized returns." In February 2026, it was reported that Johnson & Johnson is reassessing its divestiture plans for its orthopedics business, DePuy Synthes. Its originally planned spin-off IPO has been put on hold, with consideration now turning to a direct sale of this core orthopedics division for over $20 billion (approximately RMB 145 billion). The division specializes in the research, development, and production of orthopedic devices, including core products such as hip and knee replacement instruments, with sales reaching $9.3 billion in 2025.
 

In February 2026, SPH announced that the company plans to transfer its 30% equity in Sino-American Shanghai Squibb Pharmaceuticals Ltd., a participating subsidiary, through public listing at a property rights exchange. The listing price for the equity transfer will be no less than RMB 1.023 billion.
 

In January 2026, Aspen announced its plan to divest its Asia-Pacific business. It intends to sell its major assets in the Asia-Pacific region, excluding mainland China, for 26.5 billion South African Rand (approximately RMB 11.236 billion). The assets include the company’s operations in Australia, New Zealand, and other Asia-Pacific regions (excluding mainland China), which will be sold to an Australian private investment firm.
 

　　……
 

Overall, at present, numerous pharmaceutical enterprises both in China and abroad are divesting non-core assets to generate cash flow, focusing resources on high-growth, high-barrier core sectors in exchange for greater development opportunities in the future. This kind of "self-amputation for survival"-style strategic transformation will continue to emerge in the future. Against this backdrop, the competitive landscape of the global pharmaceutical industry may be reshaped.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.